{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:21:00Z","timestamp":1794406860953,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41443-025-01061-2","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:00:01Z","timestamp":1744801201000},"page":"661-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data"],"prefix":"10.1038","volume":"37","author":[{"given":"Ashkan","family":"Pourabhari Langroudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4985-2787","authenticated-orcid":false,"given":"Abby L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satvir","family":"Basran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah R.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-8657","authenticated-orcid":false,"given":"Yu-Sheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giuduce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-0141","authenticated-orcid":false,"given":"Michael L.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/dom.14903","volume":"25","author":"M Mashayekhi","year":"2023","unstructured":"Mashayekhi M, Beckman JA, Nian H, Garner EM, Mayfield D, Devin JK, et al. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: a randomized controlled trial. Diabetes Obes Metab. 2023;25:570\u201380. https:\/\/doi.org\/10.1111\/dom.14903","journal-title":"Diabetes Obes Metab"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.3390\/cancers16183224","volume":"16","author":"M Ayoub","year":"2024","unstructured":"Ayoub M, Aibani R, Dodd T, Ceesay M, Bhinder M, Faris C, et al. Risk of esophageal and gastric cancer in patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs): A national analysis. Cancers. 2024;16:3224. https:\/\/doi.org\/10.3390\/cancers16183224","journal-title":"Cancers"},{"key":"1061_CR3","unstructured":"Montero A, Sparks G, Presiado M, Hamel L.: KFF health tracking poll may 2024: the public\u2019s use and views of GLP-1 drugs. https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/ (2024). Accessed May 24 2024."},{"key":"1061_CR4","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.2024.7112","volume":"331","author":"JM Lee","year":"2024","unstructured":"Lee JM, Sharifi M, Oshman L, Griauzde DH, Chua K-P. Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020\u20132023. JAMA. 2024;331:2041\u20133. https:\/\/doi.org\/10.1001\/jama.2024.7112","journal-title":"JAMA"},{"key":"1061_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022;13:1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol"},{"key":"1061_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2337\/cd19-0100","volume":"38","author":"JP Almandoz","year":"2020","unstructured":"Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38:390\u2013402. https:\/\/doi.org\/10.2337\/cd19-0100","journal-title":"Clin Diabetes"},{"key":"1061_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2020.104778","volume":"124","author":"J Vestlund","year":"2020","unstructured":"Vestlund J, Jerlhag E. The glucagon-like peptide-1 receptor agonist, exendin-4, reduces sexual interaction behaviors in a brain site-specific manner in sexually naive male mice. Horm Behav. 2020;124:104778 https:\/\/doi.org\/10.1016\/j.yhbeh.2020.104778","journal-title":"Horm Behav"},{"key":"1061_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104687","volume":"117","author":"J Vestlund","year":"2020","unstructured":"Vestlund J, Jerlhag E. Glucagon-like peptide-1 receptors and sexual behaviors in male mice. Psychoneuroendocrinology. 2020;117:104687. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.104687","journal-title":"Psychoneuroendocrinology"},{"key":"1061_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/WNR.0b013e3280b10bfe","volume":"18","author":"JR Georgiadis","year":"2007","unstructured":"Georgiadis JR, Reinders AA, Van der Graaf FH, Paans AM, Kortekaas R. Brain activation during human male ejaculation revisited. Neuroreport. 2007;18:553\u20137. https:\/\/doi.org\/10.1097\/WNR.0b013e3280b10bfe","journal-title":"Neuroreport"},{"key":"1061_CR10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/j.1743-6109.2010.01782.x","volume":"7","author":"D Rowland","year":"2010","unstructured":"Rowland D, McMahon CG, Abdo C, Chen J, Jannini E, Waldinger MD, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2010;7:1668\u201386. https:\/\/doi.org\/10.1111\/j.1743-6109.2010.01782.x","journal-title":"J Sex Med"},{"key":"1061_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114283","volume":"442","author":"HW Jie","year":"2024","unstructured":"Jie HW, Jie W, Jianxiong M, Xin Z, Runnan X, Yijia F, et al. Mechanism of denervation muscle atrophy mediated by Ach\/p38\/MAPK pathway in rats with erectile dysfunction caused by nerve injury. Exp Cell Res. 2024;442:114283. https:\/\/doi.org\/10.1016\/j.yexcr.2024.114283","journal-title":"Exp Cell Res"},{"key":"1061_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s41043-024-00653-w","volume":"43","author":"X Jin","year":"2024","unstructured":"Jin X, Sun L, Li H, Liu Y. Association between the composite dietary antioxidant index and erectile dysfunction in US men: a cross-sectional study. J Health Popul Nutr. 2024;43:184. https:\/\/doi.org\/10.1186\/s41043-024-00653-w","journal-title":"J Health Popul Nutr"},{"key":"1061_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/00224499.2012.744953","volume":"51","author":"AL Quinta Gomes","year":"2014","unstructured":"Quinta Gomes AL, Nobre PJ. Prevalence of sexual problems in Portugal: results of a population-based study using a stratified sample of men aged 18 to 70 years. J Sex Res. 2014;51:13\u201321. https:\/\/doi.org\/10.1080\/00224499.2012.744953","journal-title":"J Sex Res"},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jama.281.6.537","volume":"281","author":"EO Laumann","year":"1999","unstructured":"Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537\u201344. https:\/\/doi.org\/10.1001\/jama.281.6.537","journal-title":"JAMA"},{"key":"1061_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/jsxmed\/qdae008","volume":"21","author":"KP Mark","year":"2024","unstructured":"Mark KP, Arenella K, Girard A, Herbenick D, Fu J, Coleman E. Erectile dysfunction prevalence in the United States: report from the 2021 national survey of sexual wellbeing. J Sex Med. 2024;21:296\u2013303. https:\/\/doi.org\/10.1093\/jsxmed\/qdae008","journal-title":"J Sex Med"},{"key":"1061_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1061_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1061_CR18","unstructured":"B\u00f6hm R.: Primer on disproportionality analysis. https:\/\/openvigil.sourceforge.net\/doc\/DPA.pdf (2018). Accessed 03\/17\/2025."},{"key":"1061_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/bmj.311.7003.485","volume":"311","author":"DG Altman","year":"1995","unstructured":"Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485. https:\/\/doi.org\/10.1136\/bmj.311.7003.485","journal-title":"BMJ"},{"key":"1061_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","volume":"64","author":"JH Watanabe","year":"2024","unstructured":"Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc. 2024;64:133\u20138. https:\/\/doi.org\/10.1016\/j.japh.2023.10.002","journal-title":"J Am Pharm Assoc"},{"key":"1061_CR21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1126\/science.adn3693","volume":"382","author":"HH Thorp","year":"2023","unstructured":"Thorp HH. More questions than answers. Science. 2023;382:1213 https:\/\/doi.org\/10.1126\/science.adn3693","journal-title":"Science"},{"key":"1061_CR22","unstructured":"(FDA) USFaDA: FDA approves new drug treatment for chronic weight management, first since 2014. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 (2021). Accessed Nov 2 2024."},{"key":"1061_CR23","unstructured":"(FDA) USFaDA: Drug approval package byetta (Exenatide) injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021773_byettatoc.cfm#:~:text=Approval%20Date%3A%204%2F28%2F2005 (2005). Accessed Nov 2 2024."},{"key":"1061_CR24","unstructured":"Jagielski D.: These were the top-selling GLP-1 drugs last quarter from Eli Lilly and Novo Nordisk. https:\/\/finance.yahoo.com\/news\/were-top-selling-glp-1-120000543.html (2024). Accessed Nov 2, 2024."},{"key":"1061_CR25","unstructured":"(FDA) USFaDA: Drug trials snapshots: MOUNJARO. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-mounjaro (2022). Accessed Nov 2 2024."},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, et al. Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184:1056\u201364. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2525","journal-title":"JAMA Intern Med"},{"key":"1061_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-024-00895-6","author":"C Able","year":"2024","unstructured":"Able C, Liao B, Saffati G, Maremanda A, Applewhite J, Nasrallah AA, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: A TriNetX database study. Int J Impot Res. 2024. https:\/\/doi.org\/10.1038\/s41443-024-00895-6","journal-title":"Int J Impot Res"},{"key":"1061_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/andr.12099","volume":"3","author":"VA Giagulli","year":"2015","unstructured":"Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabba C, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015;3:1094\u2013103. https:\/\/doi.org\/10.1111\/andr.12099","journal-title":"Andrology"},{"key":"1061_CR29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S2213-8587(21)00115-7","volume":"9","author":"HS Bajaj","year":"2021","unstructured":"Bajaj HS, Gerstein HC, Rao-Melacini P, Basile J, Colhoun H, Conget I, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol. 2021;9:484\u201390. https:\/\/doi.org\/10.1016\/S2213-8587(21)00115-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1061_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr., et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142:732\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/brainsci14060617","volume":"14","author":"D Arillotta","year":"2024","unstructured":"Arillotta D, Floresta G, Papanti Pelletier GD, Guirguis A, Corkery JM, Martinotti G, et al. Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach. Brain Sci. 2024;14:617 https:\/\/doi.org\/10.3390\/brainsci14060617","journal-title":"Brain Sci"},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fphys.2020.00555","volume":"11","author":"Z Fu","year":"2020","unstructured":"Fu Z, Gong L, Liu J, Wu J, Barrett EJ, Aylor KW, et al. Brain endothelial cells regulate glucagon-like peptide 1 entry into the brain via a receptor-mediated process. Front Physiol. 2020;11:555. https:\/\/doi.org\/10.3389\/fphys.2020.00555","journal-title":"Front Physiol"},{"key":"1061_CR33","doi-asserted-by":"publisher","unstructured":"Lengsfeld S, Hasenbohler F, Probst L, Baur F, Emara Y, Bathelt C, et al. Effects of glucagon-like peptide-1 analogs on sexual desire: a randomized, double-blind, placebo-controlled crossover trial. Endocr Abstr. 2023. https:\/\/doi.org\/10.1530\/endoabs.90.P69.","DOI":"10.1530\/endoabs.90.P69"},{"key":"1061_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.peptides.2008.04.007","volume":"29","author":"L Brunetti","year":"2008","unstructured":"Brunetti L, Orlando G, Recinella L, Leone S, Ferrante C, Chiavaroli A, et al. Glucagon-like peptide 1 (7\u201336) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus. Peptides. 2008;29:1377\u201381. https:\/\/doi.org\/10.1016\/j.peptides.2008.04.007","journal-title":"Peptides"},{"key":"1061_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1061_CR36","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/opo.12131","volume":"34","author":"RA Armstrong","year":"2014","unstructured":"Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502\u20138. https:\/\/doi.org\/10.1111\/opo.12131","journal-title":"Ophthalmic Physiol Opt"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01061-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T16:16:22Z","timestamp":1755706582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01061-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1038\/s41443-025-01061-2","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. This study utilized publicly available, de-identified data from the FDA Adverse Event Reporting System (FAERS), and therefore did not involve direct interaction with human participants or identifiable private information. As such, the Stanford University School of Medicine Institutional Review Board determined that the study was exempt from review (IRB exemption granted; no reference number applicable for de-identified dataset studies). Because the research did not involve the collection of identifiable human data or images, informed consent to participate and consent for publication were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}